Please enable JavaScript to continue using this application.

Compare $LEGN vs $PBLS | Chartloom

Compare

$LEGN vs $PBLS

Legend Biotech Corp · Parabilis Medicines Inc

LEGN

Legend Biotech Corp

PBLS

Parabilis Medicines Inc

Compare $LEGN vs $PBLS

Comparing Legend Biotech Corp and Parabilis Medicines Inc

LEGNLegend Biotech Corp

PBLSParabilis Medicines Inc

LEGNLegend Biotech Corp

Market cap

$3.62B

P/E (TTM)

—

Forward P/E (NTM)

25.42x

Forward P/S (NTM)

2.17x

Rev growth (TTM)

59.6%

YTD performance

-13.4%

52W performance

-42.2%

FCF yield

-3.4%

PBLSParabilis Medicines Inc

Market cap

$3.20B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

581.53x

Rev growth (TTM)

—

YTD performance

-13.0%

52W performance

-13.0%

FCF yield

-1.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LEGN

PBLS

Detailed metrics comparison

LEGN

Legend Biotech Corp

PBLS

Parabilis Medicines Inc

Market Cap

LEGN$3.62B

PBLS$3.20B

Enterprise Value

LEGN$3.23B

PBLS$2.12B

Price

LEGN$18.62

PBLS$27.48

P/E Ratio

LEGNN/A

PBLSN/A

P/S Ratio

LEGN2.85x

PBLS21,642.36x

EV/Sales

LEGN2.54x

PBLS14,348.08x

EV/EBITDA

LEGN0.00x

PBLS0.00x

P/B Ratio

LEGN3.04x

PBLS3.57x

P/FCF Ratio

LEGNN/A

PBLSN/A

EV/FCF

LEGN-26.50x

PBLS-39.47x

PEG Ratio

LEGNN/A

PBLSN/A

Forward P/E (NTM)

LEGN25.42x

PBLSN/A

Forward P/S (NTM)

LEGN2.17x

PBLS581.53x

Revenue (TTM)

LEGN$1.27B

PBLS$148K

Revenue Growth (YoY)

LEGN59.6%

PBLSN/A

Forward Rev Growth

LEGN25.0%

PBLS212.5%

Gross Margin (TTM)

LEGN56.6%

PBLS0.0%

Operating Margin (TTM)

LEGN0.0%

PBLS0.0%

EBITDA Margin (TTM)

LEGN-0.8%

PBLS-65635.1%

Net Margin (TTM)

LEGN-7.2%

PBLS-93131.8%

FCF Margin (TTM)

LEGN-9.6%

PBLS-36356.1%

Net Income (TTM)

LEGN$-92M

PBLS$-138M

FCF (TTM)

LEGN$-122M

PBLS$-54M

EPS (TTM)

LEGN-$0.47

PBLS-$1.12

ROE (TTM)

LEGN-870.0%

PBLS0.0%

ROA (TTM)

LEGN-539.0%

PBLS0.0%

ROIC (TTM)

LEGN-643.0%

PBLS0.0%

Cash

LEGN$673M

PBLS$1.09B

Debt

LEGN$278M

PBLS$8M

Net Cash/Debt

LEGN$395M

PBLS$1.08B

Current Ratio (TTM)

LEGN3.04x

PBLS17.91x

Quick Ratio (TTM)

LEGN2.89x

PBLS17.83x

Debt/Equity (TTM)

LEGN0.23x

PBLS0.01x

Debt/Assets (TTM)

LEGN0.0%

PBLS0.0%

Interest Coverage (TTM)

LEGNN/A

PBLSN/A

Net Debt/EBITDA (TTM)

LEGN0.00x

PBLS0.00x

Beta

LEGN0.57

PBLS-1.08

52W Performance

LEGN-42.2%

PBLS-13.0%

YTD Performance

LEGN-13.4%

PBLS-13.0%

% from 52W High

LEGN-50.3%

PBLS-35.3%

% from 52W Low

LEGN14.7%

PBLS12.1%

Asset Turnover (TTM)

LEGN0.75x

PBLS0.00x

FCF Yield (TTM)

LEGN-3.4%

PBLS-1.7%

Earnings Yield (TTM)

LEGN-2.5%

PBLS-4.3%

Dividend Yield (TTM)

LEGNN/A

PBLSN/A

Rule of 40

LEGN50.0

PBLS-36,356.1

EV/GP/RG

LEGN0.13

PBLSN/A

Ticker research

View LEGN research View PBLS research

Metric	LEGN Legend Biotech Corp	PBLS Parabilis Medicines Inc
Market & Valuation
Market Cap	$3.62B	$3.20B
Enterprise Value	$3.23B	$2.12B
Price	$18.62	$27.48
P/E Ratio	N/A	N/A
P/S Ratio	2.85x	21,642.36x
EV/Sales	2.54x	14,348.08x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.04x	3.57x
P/FCF Ratio	N/A	N/A
EV/FCF	-26.50x	-39.47x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	25.42x	N/A
Forward P/S (NTM)	2.17x	581.53x
Revenue & Growth
Revenue (TTM)	$1.27B	$148K
Revenue Growth (YoY)	59.6%	N/A
Forward Rev Growth	25.0%	212.5%
Profitability
Gross Margin (TTM)	56.6%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-0.8%	-65635.1%
Net Margin (TTM)	-7.2%	-93131.8%
FCF Margin (TTM)	-9.6%	-36356.1%
Net Income (TTM)	$-92M	$-138M
FCF (TTM)	$-122M	$-54M
EPS (TTM)	-$0.47	-$1.12
ROE (TTM)	-870.0%	0.0%
ROA (TTM)	-539.0%	0.0%
ROIC (TTM)	-643.0%	0.0%
Financial Health
Cash	$673M	$1.09B
Debt	$278M	$8M
Net Cash/Debt	$395M	$1.08B
Current Ratio (TTM)	3.04x	17.91x
Quick Ratio (TTM)	2.89x	17.83x
Debt/Equity (TTM)	0.23x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.57	-1.08
52W Performance	-42.2%	-13.0%
YTD Performance	-13.4%	-13.0%
% from 52W High	-50.3%	-35.3%
% from 52W Low	14.7%	12.1%
Efficiency & Yields
Asset Turnover (TTM)	0.75x	0.00x
FCF Yield (TTM)	-3.4%	-1.7%
Earnings Yield (TTM)	-2.5%	-4.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	50.0	-36,356.1
EV/GP/RG	0.13	N/A
Ticker research	View LEGN research	View PBLS research

Valuation

P/S Ratio

LEGN

2.85x

PBLS

21,642.36x

EV/FCF

PBLS

-39.47x

LEGN

-26.50x

Growth & revenue

Revenue Growth TTM

LEGN

59.6%

Forward Revenue Growth

PBLS

212.5%

LEGN

25.0%

Profitability & performance

Gross Margin

LEGN

56.6%

PBLS

0.0%

ROE

PBLS

0.0%

LEGN

-870.0%

FCF Yield %

PBLS

-1.7%

LEGN

-3.4%

52-Week Performance

PBLS

-13.0%

LEGN

-42.2%

Detailed metrics comparison

LEGN

Legend Biotech Corp

PBLS

Parabilis Medicines Inc

Market Cap

LEGN$3.62B

PBLS$3.20B

Enterprise Value

LEGN$3.23B

PBLS$2.12B

Price

LEGN$18.62

PBLS$27.48

P/E Ratio

LEGNN/A

PBLSN/A

P/S Ratio

LEGN2.85x

PBLS21,642.36x

EV/Sales

LEGN2.54x

PBLS14,348.08x

EV/EBITDA

LEGN0.00x

PBLS0.00x

P/B Ratio

LEGN3.04x

PBLS3.57x

P/FCF Ratio

LEGNN/A

PBLSN/A

EV/FCF

LEGN-26.50x

PBLS-39.47x

PEG Ratio

LEGNN/A

PBLSN/A

Forward P/E (NTM)

LEGN25.42x

PBLSN/A

Forward P/S (NTM)

LEGN2.17x

PBLS581.53x

Revenue (TTM)

LEGN$1.27B

PBLS$148K

Revenue Growth (YoY)

LEGN59.6%

PBLSN/A

Forward Rev Growth

LEGN25.0%

PBLS212.5%

Gross Margin (TTM)

LEGN56.6%

PBLS0.0%

Operating Margin (TTM)

LEGN0.0%

PBLS0.0%

EBITDA Margin (TTM)

LEGN-0.8%

PBLS-65635.1%

Net Margin (TTM)

LEGN-7.2%

PBLS-93131.8%

FCF Margin (TTM)

LEGN-9.6%

PBLS-36356.1%

Net Income (TTM)

LEGN$-92M

PBLS$-138M

FCF (TTM)

LEGN$-122M

PBLS$-54M

EPS (TTM)

LEGN-$0.47

PBLS-$1.12

ROE (TTM)

LEGN-870.0%

PBLS0.0%

ROA (TTM)

LEGN-539.0%

PBLS0.0%

ROIC (TTM)

LEGN-643.0%

PBLS0.0%

Cash

LEGN$673M

PBLS$1.09B

Debt

LEGN$278M

PBLS$8M

Net Cash/Debt

LEGN$395M

PBLS$1.08B

Current Ratio (TTM)

LEGN3.04x

PBLS17.91x

Quick Ratio (TTM)

LEGN2.89x

PBLS17.83x

Debt/Equity (TTM)

LEGN0.23x

PBLS0.01x

Debt/Assets (TTM)

LEGN0.0%

PBLS0.0%

Interest Coverage (TTM)

LEGNN/A

PBLSN/A

Net Debt/EBITDA (TTM)

LEGN0.00x

PBLS0.00x

Beta

LEGN0.57

PBLS-1.08

52W Performance

LEGN-42.2%

PBLS-13.0%

YTD Performance

LEGN-13.4%

PBLS-13.0%

% from 52W High

LEGN-50.3%

PBLS-35.3%

% from 52W Low

LEGN14.7%

PBLS12.1%

Asset Turnover (TTM)

LEGN0.75x

PBLS0.00x

FCF Yield (TTM)

LEGN-3.4%

PBLS-1.7%

Earnings Yield (TTM)

LEGN-2.5%

PBLS-4.3%

Dividend Yield (TTM)

LEGNN/A

PBLSN/A

Rule of 40

LEGN50.0

PBLS-36,356.1

EV/GP/RG

LEGN0.13

PBLSN/A

Ticker research

View LEGN research View PBLS research

Metric	LEGN Legend Biotech Corp	PBLS Parabilis Medicines Inc
Market & Valuation
Market Cap	$3.62B	$3.20B
Enterprise Value	$3.23B	$2.12B
Price	$18.62	$27.48
P/E Ratio	N/A	N/A
P/S Ratio	2.85x	21,642.36x
EV/Sales	2.54x	14,348.08x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.04x	3.57x
P/FCF Ratio	N/A	N/A
EV/FCF	-26.50x	-39.47x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	25.42x	N/A
Forward P/S (NTM)	2.17x	581.53x
Revenue & Growth
Revenue (TTM)	$1.27B	$148K
Revenue Growth (YoY)	59.6%	N/A
Forward Rev Growth	25.0%	212.5%
Profitability
Gross Margin (TTM)	56.6%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-0.8%	-65635.1%
Net Margin (TTM)	-7.2%	-93131.8%
FCF Margin (TTM)	-9.6%	-36356.1%
Net Income (TTM)	$-92M	$-138M
FCF (TTM)	$-122M	$-54M
EPS (TTM)	-$0.47	-$1.12
ROE (TTM)	-870.0%	0.0%
ROA (TTM)	-539.0%	0.0%
ROIC (TTM)	-643.0%	0.0%
Financial Health
Cash	$673M	$1.09B
Debt	$278M	$8M
Net Cash/Debt	$395M	$1.08B
Current Ratio (TTM)	3.04x	17.91x
Quick Ratio (TTM)	2.89x	17.83x
Debt/Equity (TTM)	0.23x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.57	-1.08
52W Performance	-42.2%	-13.0%
YTD Performance	-13.4%	-13.0%
% from 52W High	-50.3%	-35.3%
% from 52W Low	14.7%	12.1%
Efficiency & Yields
Asset Turnover (TTM)	0.75x	0.00x
FCF Yield (TTM)	-3.4%	-1.7%
Earnings Yield (TTM)	-2.5%	-4.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	50.0	-36,356.1
EV/GP/RG	0.13	N/A
Ticker research	View LEGN research	View PBLS research